862174-60-5

Basic information

• Product Name: 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt
• Synonyms: 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt;2-Oxabicyclo[2.2.1]heptan...;(1R,4R,5R)-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxylic acid;2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)-
• CAS NO: 862174-60-5
• Molecular Formula: C₇H₈O₄
• Molecular Weight: 450.5268
• Mol File: 862174-60-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 422.0±38.0 °C(Predicted)
• Appearance: /
• Density: 1.487±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.22±0.20(Predicted)
• CAS DataBase Reference: 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt(862174-60-5)
• EPA Substance Registry System: 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt(862174-60-5)

Safety Data

• Hazardous Substances Data: 862174-60-5(Hazardous Substances Data)

Usage

General Description

The chemical "2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt" is a compound formed by the reaction of cinchonidine, a natural product derived from the cinchona tree, with 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid. 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt is a salt of cinchonidine, which is a chiral molecule with multiple stereocenters. The presence of the cinchonidine salt in this compound suggests its potential use as a chiral resolving agent in asymmetric synthesis. 2-Oxabicyclo[2.2.1]heptane-5-carboxylic acid, 3-oxo-, (1R,4R,5R)- cinchonidine salt may have applications in the pharmaceutical industry for the production of enantiomerically pure compounds. Its structure and properties make it a promising candidate for use in the synthesis of complex organic molecules with high levels of stereocontrol.

Upstream product

• 1703-61-3 rac-4-oxocyclopentane-1,2-dicarboxylic acid 
• 28269-02-5 cis-4-oxo-1,2-cyclopentanedicarboxylic acid bis(methyl ester) 
• 67885-98-7 (1R,2R)-4-hydroxycyclopentane-1,2-dicarboxylic acid 
• 541-41-3 chloroformic acid ethyl ester 
• 4373-15-3 1,2,3,4-butanetetracarboxylic acid tetraethyl ester 
• 4534-68-3 1,2,3,4-butanetetracarboxylic acid 
• 1703-61-3 (1R,2R)-4-oxocyclopentane-1,2-dicarboxylic acid 
• 35079-19-7 trans-(1R,2R)-1,2-Bis(methoxycarbonyl)-4-oxocyclopentane 
• 862259-02-7 trans-(3R,4R)-3,4-bis(methoxycarbonyl)cyclopentanol 

Downstream Products

• 1042695-87-3 methyl (1R,2R,4S)-2-[5-hexen-1-yl(methyl)carbamoyl]-4-[[2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxy-8-methyl-4-quinolinyl]oxy]cyclopentanecarboxylate 
• 923604-56-2 ethyl (1R,2S)-2-ethenyl-1-({[(1R,2R,4R)-2-[hex-5-en-1-yl-(methyl)carbamoyl]-4-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)cyclopentyl]carbonyl}-amino)cyclopropanecarboxylate 
• 923604-57-3 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-10(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-(2R,3aR,10Z,11aS,2aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid ethyl ester 
• 923604-58-4 (2R,3aR,10Z,11aS,12aR,14aR)-2-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid 
• 923604-59-5 simeprevir 
• 1027355-52-7 3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid hex-5-enyl-methylamide 
• 923275-32-5 (1R,2S)-1-{[(1R,2R,4R)-4-[2-(3-fluoro-phenyl)-7-methoxy-8-methyl-quinazolin-4-yloxy]-2-(hex-5-enyl-methyl-carbamoyl)-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid ethyl ester 
• 923275-12-1 (1R,2S)-1-({(1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-[7-methoxy-2-(4-methoxy-phenyl)-8-methyl-quinazolin-4-yloxy]-cyclopentanecarbonyl}-amino)-2-vinyl-cyclopropanecarboxylic acid ethyl ester 
• 923274-44-6 (1R,2R,4R)-4-(2-phenyl-quinazolin-4-yloxy)-cyclopentane-1,2-dicarboxylic acid 1-[((1R,2S)-1 cyclo-propanesulfonecarbonyl-2-vinylcyclopropyl)-amide] 2-(hex-5-enylmethylamide) 
• 923274-31-1 (1R,2S)-ethyl 1-((1R,2R,4R)-2-(hex-5-enyl(methyl)carbamoyl)-4-(7-methoxy-2-phenylquinazolin-4-yloxy)cyclopentanecarboxamido)-2-vinylcyclopropanecarboxylate 
• 923275-30-3 (1R,2R,4R)-2-((1R,2S)-1-ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-[2-(3-fluoro-phenyl)-7-methoxy-8-methyl-quinazolin-4-yloxy]-cyclopentanecarboxylic acid tert-butyl ester 
• 923275-10-9 (1R,2R,4R)-2-((1R,2S)-1-ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-[7-methoxy-2-(4-methoxy-phenyl)-8-methyl-quinazolin-4-yloxy]-cyclopentanecarboxylic acid tert-butyl ester 
• 923275-11-0 (1R,2R,4R)-2-((1R,2S)-1-ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-[7-methoxy-2-(4-methoxy-phenyl)-8-methyl-quinazolin-4-yloxy]-cyclopentanecarboxylic acid 
• 923274-42-4 (1R,2S)-1-{[(1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-(2-phenyl-quinazolin-4-yloxy)-cyclo-pentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid ethyl ester 

Relevant articles and documents

Ring-Closing Metathesis on Commercial Scale: Synthesis of HCV Protease Inhibitor Simeprevir

The key macrocyclization step in the synthesis of simeprevir, a hepatitis C virus (HCV) antiviral drug, was studied. N-Boc substitution on the diene precursor changes the site of insertion of the metathesis catalyst and, consequently, the kinetic model of the ring closing metathesis (RCM), enabling a further increase in the macrocyclization efficiency under simulated high dilution (SHD) conditions. NMR of the inserted species of both first and second generation RCM catalysts are reported and discussed.

PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(-)- ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis- (1R,2S)-(-)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(-)-ephedrine from the precipitated salt obtained in step (b).

CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS

The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic P2 unit. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.